Evaluation of a Diabetes Treatment and Education Program for Insulin Pump Therapy (INPUT) (INPUT)
24 november 2017 bijgewerkt door: Norbert Hermanns
Evaluation of a Newly Developed Treatment and Education Program (INPUT) for Diabetic Patients Performing an Insulin Pump Therapy
This study is a randomized, controlled, prospective trial with a 6-month follow-up.
A newly developed treatment and education programme for diabetic patients with an insulin pump therapy (INPUT) will be tested compared to a waiting group.
Primary outcome variable is the difference in glycemic control between baseline and the 6-month follow-up.
Secondary outcome variables are: severe hypoglycaemia, diabetes-related distress, depressive symptoms, health-related quality of life, diabetes empowerment, self-care behavior, hypoglycemia awareness, and attitudes towards insulin pump therapy.
Studie Overzicht
Gedetailleerde beschrijving
INPUT is a self-management-based treatment and education program for diabetic patients with an insulin pump (CSII). It is designed to empower patients to adequately perform their therapy in daily life and to integrate their diabetes and their insulin pump into their lifes in order to enhance quality of life.
INPUT ist tested in an randomized controlled trial (RCT) with a waiting-list control group since no certified and effective treatment and education program for CSII exists.
This study is a multi-center study. Study centers are specialized diabetes practices throughout Germany. Patients will be approached by their respective practice and informed about the study. Study measurements as well as the conduct of INPUT will take place at the respective practice.
Baseline measurement will take place 2 weeks prior to the beginning of INPUT. After completion of baseline measurement, all patients from one study center will be randomized centrally by the Research Institute of the Diabetes Academy Mergentheim (FIDAM). 2 weeks and 6 months after the completion of INPUT, follow-up measurements will be conducted at the respective study center.
HbA1c as a marker of glycemic control will be analyzed in a central laboratory. Secondary outcome measures will be assessed via psychometrically tested questionnaires, Case Reports Forms, or patient files.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
268
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Neuss, Duitsland, 41462
- Diabetologische Schwerpunktpraxis Neuss
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
16 jaar tot 75 jaar (Kind, Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Existing insulin pump therapy
- Prior participation in a structured diabetes education program
- HbA1c ≥ 7,5% but ≤ 13%
- Ability to understand, speak and write German language
- informed consent (if necessary, informed consent of the parents)
Exclusion Criteria:
- Diabetes duration < 1 year
- severe organic disease preventing a regular participation in the training course
- pregnancy
- severe cognitive impairment
- current treatment of psychiatric disorder
- renal disease requiring dialysis
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: INPUT
INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump.
Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life.
Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
|
Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
Andere namen:
|
|
Geen tussenkomst: Waiting list
Patients are randomly assigned to the waiting list.
After completion of the 6-month follow-up, these patients will also receive training with INPUT.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in Glycemic Control Measured by A1c
Tijdsspanne: 6 months
|
Difference between baseline A1c and A1c at the 6-month follow-up
|
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hypoglycaemia Awareness
Tijdsspanne: 6 months
|
The hypoglycemia awareness questionnaire provides a score indicating the severity of hypoglycaemia unawareness.
This scale ranges from 0 (maximum hypoglycaemia awareness) to 7 (minimum hypoglycaemia awareness), where a score of 4 suggests reduced hypoglycaemia awareness.
|
6 months
|
|
Diabetes Empowerment
Tijdsspanne: 6 months
|
Empowerment is measured by a German version of the Diabetes Empowerment Scale, a measure of diabetes-related psychosocial self-efficacy.
|
6 months
|
|
Problem Areas in Diabetes
Tijdsspanne: 6 months
|
The Problem Areas in Diabetes Scale (PAID) assesses the psychosocial adaptation to the burden of living with and treating diabetes.
|
6 months
|
|
Satisfaction with current treatment
Tijdsspanne: 6 months
|
Satisfaction with current treatment is assessed via a 10-item scale.
The total score ranges from 10 to 60 with lower scores indicating higher satisfaction.
|
6 months
|
|
Diabetes Self-Management
Tijdsspanne: 6 months
|
The Diabetes Self-Management Questionnaire is a self-report measure of patients' self-care.
The level of self-care is assessed via Likert scales.
|
6 months
|
|
Diabetes Distress
Tijdsspanne: 6 months
|
The Diabetes Distress Scale (DDS) assesses diabetes-related stressors due to living and treating diabetes.
Different aspects of distress are covered: emotional burden, physician-related, regimen-related, diabetes-related interpersonal
|
6 months
|
|
Health-related Quality of Life
Tijdsspanne: 6 months
|
Health-related quality of life focuses on the health-specific aspects of quality of life and dealing with a chronic condition such as diabetes
|
6 months
|
|
Depressive symptoms
Tijdsspanne: 6 months
|
The presence and extent of typical depressive symptoms are assessed via self-report
|
6 months
|
|
Attitudes towards insulin pump therapy
Tijdsspanne: 6 months
|
Specific attitudes towards different aspects of insulin pump therapy are assessed via Likert scales.
The questionnaire consists of 6 subscales that can be placed within 4 dimensions: (I) Expectations on insulin pump therapy (subscale: achieving better glycaemic control) (II) Perceived advantages of an insulin pump (subscale: gaining more flexibility) (III) Ease of use (subscales: design + functionality) (IV) Psychosocial effects and barriers (subscales: technological dependence + impaired body image)
|
6 months
|
|
Severe hypoglycaemia
Tijdsspanne: 6 months
|
The incidence of severe hypoglycaemia in the past six months is assessed via Case Report Forms.
Severe hypoglycaemia is defined as requiring third party assistance or medical intervention for treating hypoglycaemia.
|
6 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Norbert Hermanns, PhD, Forschungsinstitut der Diabetes Akademie Mergentheim (FIDAM GmbH)
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 april 2016
Primaire voltooiing (Werkelijk)
1 februari 2017
Studie voltooiing (Werkelijk)
1 maart 2017
Studieregistratiedata
Eerst ingediend
20 april 2016
Eerst ingediend dat voldeed aan de QC-criteria
11 augustus 2016
Eerst geplaatst (Schatting)
16 augustus 2016
Updates van studierecords
Laatste update geplaatst (Werkelijk)
28 november 2017
Laatste update ingediend die voldeed aan QC-criteria
24 november 2017
Laatst geverifieerd
1 november 2017
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NH012016
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .